Experts Analysis on Share Price: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) soared 0.80% during previous trade, a total of 6.40M shares exchanged hands compared with its average trading volume of 9.07M shares whereas its relative volume is 0.70. The stock has a market capitalization of $78.16B along with 1.73B outstanding shares. Stock’s intraday price range hit the peak level of $45.46 and touched the lowest level of $44.92.

Most recently Abbott Laboratories (NYSE:ABT)’s price target was revised on 03/02/17 and according to 13 analysts stock’s price will reach at $47.77 during 52 weeks with standard deviation of 2.83. Stock’s minimum price target estimates has been figured out at $41 while the maximum price target forecast is established at $51, if we look at the price target with an optimistic approach it has upside potential of 12% from its latest closing price of $45.36.

Historically, if we look at price target revisions, two weeks ago Abbott Laboratories (NYSE:ABT)’s price target was revised on 2/17/17 by the analysts, however the bullish price estimates of the stock set at $51 while the bearish estimates kept at $42 over the next one year. Stock’s 52-week target was retained at $47.56, the estimates indicates a standard deviation of 2.79.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.67. ABR value is precisely based on brokerage recommendations, where out of 15 brokerage recommendations 9 rate Abbott Laboratories (NYSE:ABT) stock a Strong Buy, 2 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 6/21/16 the stock of Abbott Laboratories (NYSE:ABT) upgraded by Edward Jones from Hold to Buy. However previously on 1/4/16 it was downgraded by Morgan Stanley from Overweight to Equal-Weight. A research note issued on 11/13/15 the stock was downgraded by Goldman from Buy to Neutral.

Abbott Laboratories (NYSE:ABT) performance over the past one year soared 18.74% whereas its year to date (YTD) performance indicated a bullish trend of 18.86%. During the last six months the stock climbed 8.97%. Quarterly performance of the company shows optimistic momentum of 18.80% while its last one month trend is positive with 6.91%. Stock’s weekly performance expressed down trend of -0.50%.

The company’s price sits 8.10% above from its 50-day moving average of $43.06 and 11.34% far from the stock’s 200-day moving average which is $41.11. Abbott Laboratories (NYSE:ABT)’s shares are currently trading -1.05% away from the 52-week high price of $45.84 and +25.75% far from the 52-week low price of $36.07.

According to consensus agreement of 14 analysts Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.43 in their quarterly report and it is expected to announce the company’s results on 4/19/17. For the current quarter the company has high EPS estimates of $0.43 in contradiction of low EPS estimates of $0.43. However a year ago for the same quarter the company has reported $0.41 EPS. Current year EPS projections for Abbott Laboratories (NYSE:ABT) set at $2.45 according to the sentiments of 17 analysts, while its lowest earnings estimates are $2.43 and highest earnings estimates are $2.48.

According to 13 analysts, Abbott Laboratories (NYSE:ABT)’s revenue estimates for the current quarter are $6.16B meanwhile the company has high revenue estimates of $6.36B in contradiction of low revenue estimates of $6.01B. For the current year the company’s revenue estimates are $26.13B compared to low analyst estimates of $25.88B and high estimates of $26.65B according to the projection of 16 analysts.

How Big Insider Trading Can Impact Abbott Laboratories (NYSE:ABT) Stock?

Abbott Laboratories (NYSE:ABT) exchanged hands 11,164,100 shares versus average trading capacity of 9.31M shares, while its relative trading volume is 1.21. Abbott Laboratories (NYSE:ABT)’s total market worth is $79.13B along with 1.73B outstanding shares.

Insiders has most recently took part in a trading activity, Watkin Jared, Senior Vice President of the company in a transaction that occurred 3/1/2017 sold 970 shares of the stock. The stock was sold at a price of $45.39, for a total value of $44,028. Subsequent to the transaction Watkin Jared owned a total of 48,511 shares of the stock.

In a separate transaction on 3/1/2017, Salvadori Daniel Gesua Sive, Senior Vice President sold 2,066 shares of the stock. The stock was sold at a price of $45.39, for a total worth of $93,776. Succeeding to the transaction Salvadori Daniel Gesua Sive owned overall 72,112 shares of the stock.

Moreover, Yoor Brian B, Executive Vice President & CFO sold 1,728 shares of the stock in a reserved transaction that ensued on 3/1/2017. At a price of $45.39, the stock was sold for an entire value of $78,434. Consequent to the transaction Yoor Brian B owned a total of 63,425 shares of the stock.

Currently, 0.30% shares of Abbott Laboratories (NYSE:ABT) are owned by insiders with 4.33% six-month change in the insider ownership. The insider filler data counts the number of monthly positions over 3 month and 12 month time spans. For Abbott Laboratories (NYSE:ABT) total 43 number of trades held during last 3 months and 94 during last 12 months, out of them 24 numbers of buys held in last 3 months and 51 buys in last 12 months. Whereas 19 numbers of sells held in last 3 months and 43 sells over the past 12 months.

For the duration of last three months Abbott Laboratories (NYSE:ABT)’s total number of shares bought are 1,529,483 and sold 181,180 from a total of 1,710,663 traded shares. During last twelve months 2,702,757 number of shares bought and 356,475 sold from a total of 3,059,232 shares traded. A net activity of 1,348,303 took place in the course of three months, while 2,346,282 during last twelve months. Insider trading information is derived from Forms 3 and 4 filings are filed with the U.S. Securities and Exchange Commission (SEC).

Abbott Laboratories (NYSE:ABT) ended last trading session at the price of $45.69 whereas a number of traders indicating mean target price will hit $47.77 over the next twelve months, mean value of price target most recently revised on 03/01/17. Abbott Laboratories (NYSE:ABT)’s highest estimates of price target are $51.00 and low forecast is $41.00 based on the opinion of 13 analysts. The price target estimates represents a standard deviation of 2.83. However brokerage recommendations suggests an ABR of 1.67 based on calls of 15 experts.

Abbott Laboratories (NYSE:ABT) is expected to release the earnings of its current quarter on 4/19/17. The company is expected to release $0.43 EPS during current quarter according to 14 analysts whereas the company reported $0.41 EPS during same quarter a year ago. For the current quarter the stock has a lowest EPS estimates of $0.43 and high estimate of $0.43. Abbott Laboratories (NYSE:ABT)’s average revenue estimates for the current quarter are $6.16B according to 13 number of analysts. However its lowest revenue estimates are $6.01B and highest revenue estimates are $6.36B. A year ago the company’s sales were $4.88B. Its yearly sales growth estimates are 26.10%. Past 5 years growth of Abbott Laboratories (NYSE:ABT) observed at -14.79%, and for the next five years the analysts that follow this company are expecting its growth at 11.24%.

Stock Overbuying Recap: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) share price soared 0.72% or +0.32 points to reach at $45.01 during previous trading session. The stock’s price fluctuated within the range of $44.54 – $45.15 during previous trading session. A total of 11,059,400 shares exchanged hands, whereas the company’s average trading volume stands at 9.28M shares. Abbott Laboratories (NYSE:ABT) has a market capitalization of $78.64B and most recently 1.73B outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Abbott Laboratories (NYSE:ABT) is at 84.51.

According to sentiments of 13 analysts the mean estimates of short term price target for the company’s stock is marked at $47.46. The most optimistic analyst sees the stock reaching $51.00 while the most conventional predicts the target price at $41.00.

The consensus mean EPS for the current quarter is at $0.43 derived from a total of 14 estimates. According to analysts minimum EPS for the current quarter is expected at $0.43 and can go high up to $0.43. However a year ago during same quarter Abbott Laboratories (NYSE:ABT) reported $0.41 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $0.6 per share according to consensus of 14 analysts.

According to sentiments of 13 analysts the company is expected to report revenues of $6.16B for the current quarter. Bearish revenue estimates established at $6.01B while the bullish revenue forecast has been figured out at $6.36B.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 1.82 on the shares of Abbott Laboratories (NYSE:ABT). Out of rating recommendations 7 have given the stock a Buy while 6 recommend the stock as Outperform. 4 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Abbott Laboratories (NYSE:ABT)’s distance from 20 day simple moving average is 6.37% whereas its distance from 50 day simple moving average is 11.27% along with 11.70% distance from 200 day simple moving average.

An important factor to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Abbott Laboratories (NYSE:ABT) shares were trading -0.44% below from the 52-week high mark of $45.21 and +24.78% above from the 52-week bottom of $36.07. The stock hit its 52-week high price on 08/02/16, and 52-week low price on 06/27/16.

When we have a peek on stock’s historical trends we come to know that, the stock has climbed 4.14% in the past one week and soared 11.25% during previous one month drive, the stock went up 12.16% during past quarter. In the last six months the stock’s performance soared 3.05% while yearly performance of the company advanced 17.85%. The company’s year to date (YTD) performance is at 17.94%.

Average true range (ATR-14) of the company sets at 0.62, along with its weekly and monthly volatility of 1.43%, 1.45% respectively. Beta value of the stock stands at 1.43.

Stock Estimates Record: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) plunged -0.07% or -0.03 points during previous trade after opening at the price of $40.32, a total of 7,748,000 shares exchanged hands compared with its average trading volume of 8.90M shares. The stock has a market capitalization of $69.38B and it has 1.47B outstanding shares.

According to consensus agreement of 14 analysts Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.65 in their quarterly report and it is expected to announce the company’s results on 1/25/17 Before Market Open. The stock lost almost -2.0% in price since last earning report, when its share price was $41.17. For the current quarter the company has highest EPS estimates of $0.66 and low forecast is $0.63. However a year ago for the same quarter the company has reported $0.62 earnings per share.

Earnings reaction history indicates that share price went down 15 times out of last 28 quarters. In Abbott Laboratories (NYSE:ABT)’s last 12 earnings reports, it has beaten EPS estimates 91% of the time. However it has meet the estimates 1 time and missed 0 time.

If we have a peek on EPS and surprise factor history during last four quarters, for the previous quarter ended on 9/2016, the consensus mean EPS was $0.58 while Abbott Laboratories (NYSE:ABT) reported $0.59 EPS on 10/19/2016 Before Market Open with a difference of 0.01 marking a surprise factor of 1.72%. The stock’s next day closing price was $40.01 with the loss of -2.82% in its share price. On seventh day of the earnings report price change of the stock was -2.38%.

Previously for the quarter ended on 6/2016, Abbott Laboratories (NYSE:ABT)’s expected mean EPS was $0.53, the company reported its quarterly earnings per share of $0.55 on 7/20/2016 Before Market Open, beating the analysts’ consensus estimate by 0.02 with surprise factor of 3.77%. The stock’s closing price was $42.38 with the gain of 2.02% in its share price on the day following the earning announcement. However price change of the stock was 4.31% on seventh day of the earnings report.

Abbott Laboratories (NYSE:ABT)’s mean EPS estimate was $0.39 for the quarter ended on 3/2016, while it reported EPS of $0.41 on 4/20/2016 Before Market Open, beating the analysts’ consensus estimate by 0.02 with surprise factor of 5.13%. On next day when data was publically announced, the stock’s closing price was $43.42 with 0.25% gain in its share price. On seventh day of the earnings report price change of the stock was up 0.05%.

Back on 1/28/2016 the company’s estimated EPS value was $0.61 and it reported $0.62 earnings per share (EPS) for the quarter ended on 12/2015. The company posted a positive surprise factor of 1.64% by 0.01.

Average EPS forecast for the current year is $2.2 according to 17 analysts making projections for Abbott Laboratories (NYSE:ABT). The most expectant earnings per share estimate of the stock is set at $2.23 while the conservative estimates kept at $2.19 over the current year. Having a look at the historical EPS report, the company attained $2.15 EPS for the previous year. While revenue estimates for the current year is $20.9B, Abbott Laboratories (NYSE:ABT) setting the highest revenues estimates of $20.97B and indicating lowest revenues at $20.81B according to agreement of 16 number of analysts. Current quarter revenue movements show that, the company has set average revenue estimates of $5.38B covering forecast of 13 analysts. The company indicates a peak revenue level of $5.45B and $5.29B at bottom level.

Having a glance at growth estimates of the company, it has current quarter growth estimates of 4.80% whereas for next quarter it has 22.00% estimations over growth. Its forecasts over growth are 2.30% during current year while analysts’ growth estimation for the next year is 11.80%. Past 5 years growth of Abbott Laboratories (NYSE:ABT) observed at -17.27%, and for the next five years the analysts that follow this company are expecting its growth at 10.14%.

Abbott Laboratories (NYSE:ABT) reached at $40.31 price level during last trade its distance from 20 days simple moving average is 1.57%, and its distance from 50 days simple moving average is 3.06% while it has a distance of 0.25% from the 200 days simple moving average. One year trading price range hit the peak level of $45.21 and touched the lowest level of $35.11. The company’s distance from 52-week high price is -10.84% and current price is above +14.81% from 52-week low price.

Stock under Consideration: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) share price soared 0.52% or +0.21 points to reach at $40.93 during previous trading session. The stock’s price fluctuated within the range of $40.69 – $41.36 during previous trading session. A total of 9,533,300 shares exchanged hands, whereas the company’s average trading volume stands at 9.14M shares. Abbott Laboratories (NYSE:ABT) has a market capitalization of $71.02B and most recently 1.47B outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Abbott Laboratories (NYSE:ABT) is at 68.33.

According to sentiments of 13 analysts the mean estimates of short term price target for the company’s stock is marked at $46.69. The most optimistic analyst sees the stock reaching $50.00 while the most conventional predicts the target price at $41.00.

The consensus mean EPS for the current quarter is at $0.65 derived from a total of 14 estimates. According to analysts minimum EPS for the current quarter is expected at $0.63 and can go high up to $0.66. However a year ago during same quarter Abbott Laboratories (NYSE:ABT) reported $0.62 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $0.49 per share according to consensus of 7 analysts.

According to sentiments of 13 analysts the company is expected to report revenues of $5.39B for the current quarter. Bearish revenue estimates established at $5.33B while the bullish revenue forecast has been figured out at $5.45B.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 1.82 on the shares of Abbott Laboratories (NYSE:ABT). Out of rating recommendations 7 have given the stock a Buy while 6 recommend the stock as Outperform. 4 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Abbott Laboratories (NYSE:ABT)’s distance from 20 day simple moving average is 5.07% whereas its distance from 50 day simple moving average is 5.20% along with 1.75% distance from 200 day simple moving average.

Important factors to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Abbott Laboratories (NYSE:ABT) shares were trading -9.46% below from the 52-week high mark of $45.21 and +16.57% above from the 52-week bottom of $35.11. The stock hit its 52-week high price on 08/02/16, and 52-week low price on 01/28/16.

When we have a peek on stock’s historical trends we come to know that, the stock has climbed 1.02% in the past one week and soared 4.45% during previous one month drive, the stock went up 0.52% during past quarter. In the last six months the stock’s performance fell -1.53% while yearly performance of the company advanced 2.11%. The company’s year to date (YTD) performance is at 7.25%.

While taking a glance at financials, we can look at a number of key indicators. Abbott Laboratories (NYSE:ABT) has a Return on Assets (ROA) of 3.40%. The company currently has a Return on Equity (ROE) of 6.60% and a Return on Investment (ROI) of 7.70%. Average true range (ATR-14) of the company sets at 0.71, along with its weekly and monthly volatility of 1.66%, 1.79% respectively. Beta value of the stock stands at 1.41.

The company’s price to free cash flow for trailing twelve months is 235.87. Its quick ratio for most recent quarter is 1.20 along with current ratio for most recent quarter of 1.60. Total debt to equity ratio of the company for most recent quarter is 0.38 whereas long term debt to equity ratio for most recent quarter is 0.29.

Analyst’s Estimates on Shares’ Price: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) soared 1.35% during previous trade, a total of 9.26M shares exchanged hands compared with its average trading volume of 9.31M shares whereas its relative volume is 1.01. The stock has a market capitalization of $60.73B along with 1.47B outstanding shares. Stock’s intraday price range hit the peak level of $41.62 and touched the lowest level of $40.78.

Most recently Abbott Laboratories (NYSE:ABT)’s price target was revised on 01/06/17 and according to 13 analysts stock’s price will reach at $46.62 during 52 weeks with standard deviation of 2.62. Stock’s minimum price target estimates has been figured out at $41 while the maximum price target forecast is established at $50, if we look at the price target with an optimistic approach it has upside potential of 21% from its latest closing price of $41.29.

Historically, if we look at price target revisions, two weeks ago Abbott Laboratories (NYSE:ABT)’s price target was revised on 12/21/16 by the analysts, however the bullish price estimates of the stock set at $50 while the bearish estimates kept at $45 over the next one year. Stock’s 52-week target was retained at $47.50, the estimates indicates a standard deviation of 2.07.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.60. ABR value is precisely based on brokerage recommendations, where out of 15 brokerage recommendations 10 rate Abbott Laboratories (NYSE:ABT) stock a Strong Buy, 1 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 6/21/16 the stock of Abbott Laboratories (NYSE:ABT) upgraded by Edward Jones from Hold to Buy. However previously on 1/4/16 it was downgraded by Morgan Stanley from Overweight to Equal-Weight. A research note issued on 11/13/15 the stock was downgraded by Goldman from Buy to Neutral.

Abbott Laboratories (NYSE:ABT) performance over the past one year soared 3.93% whereas its year to date (YTD) performance indicated a bullish trend of 7.50%. During the last six months the stock slipped -1.56%. Quarterly performance of the company shows declining momentum of -4.48% while its last one month trend is positive with 6.57%. Stock’s weekly performance expressed up trend of 5.74%.

The company’s price sits 5.69% above from its 50-day moving average of $38.82 and 2.01% far from the stock’s 200-day moving average which is $41.12. Abbott Laboratories (NYSE:ABT)’s shares are currently trading -9.25% away from the 52-week high price of $45.50 and +16.84% far from the 52-week low price of $35.34.

According to consensus agreement of 13 analysts Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.65 in their quarterly report and it is expected to announce the company’s results on 1/25/17 Before Market Open. For the current quarter the company has high EPS estimates of $0.66 in contradiction of low EPS estimates of $0.63. However a year ago for the same quarter the company has reported $0.62 EPS. Current year EPS projections for Abbott Laboratories (NYSE:ABT) set at $2.21 according to the sentiments of 17 analysts, while its lowest earnings estimates are $2.19 and highest earnings estimates are $2.23.

According to 12 analysts, Abbott Laboratories (NYSE:ABT)’s revenue estimates for the current quarter are $5.39B meanwhile the company has high revenue estimates of $5.44B in contradiction of low revenue estimates of $5.33B. For the current year the company’s revenue estimates are $20.9B compared to low analyst estimates of $20.85B and high estimates of $20.96B according to the projection of 15 analysts.

Analyst Viewpoints on Price Reaction History: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) soared 0.16% during previous trade, a total of 7.98M shares exchanged hands compared with its average trading volume of 9.05M shares whereas its relative volume is 0.94. The stock has a market capitalization of $56.45B along with 1.47B outstanding shares. Stock’s intraday price range hit the peak level of $38.34 and touched the lowest level of $37.91.

Most recently Abbott Laboratories (NYSE:ABT)’s price target was revised on 12/21/16 and according to 13 analysts stock’s price will reach at $47.23 during 52 weeks with standard deviation of 2.07. Stock’s minimum price target estimates has been figured out at $43 while the maximum price target forecast is established at $50, if we look at the price target with an optimistic approach it has upside potential of 31% from its latest closing price of $38.29.

Historically, if we look at price target revisions, two weeks ago Abbott Laboratories (NYSE:ABT)’s price target was revised on 11/18/16 by the analysts, however the bullish price estimates of the stock set at $50 while the bearish estimates kept at $45 over the next one year. Stock’s 52-week target was retained at $48, the estimates indicates a standard deviation of 1.76.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.60. ABR value is precisely based on brokerage recommendations, where out of 15 brokerage recommendations 10 rate Abbott Laboratories (NYSE:ABT) stock a Strong Buy, 1 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 6/21/16 the stock of Abbott Laboratories (NYSE:ABT) upgraded by Edward Jones from Hold to Buy. However previously on 1/4/16 it was downgraded by Morgan Stanley from Overweight to Equal-Weight. A research note issued on 11/13/15 the stock was downgraded by Goldman from Buy to Neutral.

Abbott Laboratories (NYSE:ABT) performance over the past one year plunged -12.96% whereas its year to date (YTD) performance indicated a bearish trend of -12.59%. During the last six months the stock climbed 2.27%. Quarterly performance of the company shows declining momentum of -8.67% while its last one month trend is positive with 0.50%. Stock’s weekly performance expressed down trend of -1.64%.

The company’s price sits -2.81% below from its 50-day moving average of $39.01 and -5.48% below from the stock’s 200-day moving average which is $40.97. Abbott Laboratories (NYSE:ABT)’s shares are currently trading -15.85% away from the 52-week high price of $45.50 and +8.35% far from the 52-week low price of $35.34.

According to consensus agreement of 13 analysts Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.65 in their quarterly report and it is expected to announce the company’s results on 1/25/17 Before Market Open. For the current quarter the company has high EPS estimates of $0.66 in contradiction of low EPS estimates of $0.64. However a year ago for the same quarter the company has reported $0.62 EPS. Current year EPS projections for Abbott Laboratories (NYSE:ABT) set at $2.21 according to the sentiments of 17 analysts, while its lowest earnings estimates are $2.19 and highest earnings estimates are $2.23.

According to 12 analysts, Abbott Laboratories (NYSE:ABT)’s revenue estimates for the current quarter are $5.41B meanwhile the company has high revenue estimates of $5.44B in contradiction of low revenue estimates of $5.35B. For the current year the company’s revenue estimates are $20.92B compared to low analyst estimates of $20.87B and high estimates of $20.96B according to the projection of 15 analysts.

Analysts Alert on Price Target: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) soared 0.80% during previous trade, a total of 7.25M shares exchanged hands compared with its average trading volume of 8.45M shares whereas its relative volume is 0.87. The stock has a market capitalization of $55.11B along with 1.47B outstanding shares. Stock’s intraday price range hit the peak level of $38.08 and touched the lowest level of $37.60.

Most recently Abbott Laboratories (NYSE:ABT)’s price target was revised on 11/18/16 and according to 13 analysts stock’s price will reach at $47.38 during 52 weeks with standard deviation of 1.76. Stock’s minimum price target estimates has been figured out at $43 while the maximum price target forecast is established at $50, if we look at the price target with an optimistic approach it has upside potential of 25% from its latest closing price of $37.90.

Historically, if we look at price target revisions, two weeks ago Abbott Laboratories (NYSE:ABT)’s price target was revised on 11/14/16 by the analysts, however the bullish price estimates of the stock set at $50 while the bearish estimates kept at $45 over the next one year. Stock’s 52-week target was retained at $48.18, the estimates indicates a standard deviation of 1.78.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.60. ABR value is precisely based on brokerage recommendations, where out of 15 brokerage recommendations 10 rate Abbott Laboratories (NYSE:ABT) stock a Strong Buy, 1 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 6/21/16 the stock of Abbott Laboratories (NYSE:ABT) upgraded by Edward Jones from Hold to Buy. However previously on 1/4/16 it was downgraded by Morgan Stanley from Overweight to Equal-Weight. A research note issued on 11/13/15 the stock was downgraded by Goldman from Buy to Neutral.

Abbott Laboratories (NYSE:ABT) performance over the past one year plunged -12% whereas its year to date (YTD) performance indicated a bearish trend of -13.48%. During the last six months the stock slipped -2.03%. Quarterly performance of the company shows declining momentum of -9.38% while its last one month trend is negative with -2.07%. Stock’s weekly performance expressed down trend of -3.22%.

The company’s price sits -6.10% below from its 50-day moving average of $39.67 and -6.41% below from the stock’s 200-day moving average which is $40.96. Abbott Laboratories (NYSE:ABT)’s shares are currently trading -16.70% away from the 52-week high price of $45.50 and +7.25% far from the 52-week low price of $35.34.

According to consensus agreement of 13 analysts Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.65 in their quarterly report and it is expected to announce the company’s results on 1/26/17. For the current quarter the company has high EPS estimates of $0.66 in contradiction of low EPS estimates of $0.64. However a year ago for the same quarter the company has reported $0.62 EPS. Current year EPS projections for Abbott Laboratories (NYSE:ABT) set at $2.21 according to the sentiments of 17 analysts, while its lowest earnings estimates are $2.19 and highest earnings estimates are $2.23.

According to 12 analysts, Abbott Laboratories (NYSE:ABT)’s revenue estimates for the current quarter are $5.41B meanwhile the company has high revenue estimates of $5.44B in contradiction of low revenue estimates of $5.35B. For the current year the company’s revenue estimates are $20.93B compared to low analyst estimates of $20.87B and high estimates of $20.96B according to the projection of 15 analysts.

Price Reaction History Under Analysts Radar: Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) plunged -2.34% during previous trade, a total of 11.19M shares exchanged hands compared with its average trading volume of 8.67M shares whereas its relative volume is 1.26. The stock has a market capitalization of $57.05B along with 1.47B outstanding shares. Stock’s intraday price range hit the peak level of $40.17 and touched the lowest level of $39.10.

Most recently Abbott Laboratories (NYSE:ABT)’s price target was revised on 11/11/16 and according to 13 analysts stock’s price will reach at $47.38 during 52 weeks with standard deviation of 1.78. Stock’s minimum price target estimates has been figured out at $43 while the maximum price target forecast is established at $50, if we look at the price target with an optimistic approach it has upside potential of 25% from its latest closing price of $39.20.

Historically, if we look at price target revisions, two weeks ago Abbott Laboratories (NYSE:ABT)’s price target was revised on 10/20/16 by the analysts, however the bullish price estimates of the stock set at $50 while the bearish estimates kept at $45 over the next one year. Stock’s 52-week target was retained at $48.59, the estimates indicates a standard deviation of 1.46.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.60. ABR value is precisely based on brokerage recommendations, where out of 15 brokerage recommendations 10 rate Abbott Laboratories (NYSE:ABT) stock a Strong Buy, 1 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 6/21/16 the stock of Abbott Laboratories (NYSE:ABT) upgraded by Edward Jones from Hold to Buy. However previously on 1/4/16 it was downgraded by Morgan Stanley from Overweight to Equal-Weight. A research note issued on 11/13/15 the stock was downgraded by Goldman from Buy to Neutral.

Abbott Laboratories (NYSE:ABT) performance over the past one year plunged -8.58% whereas its year to date (YTD) performance indicated a bearish trend of -10.52%. During the last six months the stock climbed 5.26%. Quarterly performance of the company shows declining momentum of -12.18% while its last one month trend is negative with -3.90%. Stock’s weekly performance expressed down trend of -1.66%.

The company’s price sits -4.22% below from its 50-day moving average of $40.83 and -2.87% below from the stock’s 200-day moving average which is $40.92. Abbott Laboratories (NYSE:ABT)’s shares are currently trading -13.85% away from the 52-week high price of $45.50 and +10.93% far from the 52-week low price of $35.34.

According to consensus agreement of 13 analysts Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.65 in their quarterly report and it is expected to announce the company’s results on 1/26/17. For the current quarter the company has high EPS estimates of $0.66 in contradiction of low EPS estimates of $0.64. However a year ago for the same quarter the company has reported $0.62 EPS. Current year EPS projections for Abbott Laboratories (NYSE:ABT) set at $2.21 according to the sentiments of 17 analysts, while its lowest earnings estimates are $2.19 and highest earnings estimates are $2.23.

According to 12 analysts, Abbott Laboratories (NYSE:ABT)’s revenue estimates for the current quarter are $5.41B meanwhile the company has high revenue estimates of $5.44B in contradiction of low revenue estimates of $5.35B. For the current year the company’s revenue estimates are $20.93B compared to low analyst estimates of $20.87B and high estimates of $20.96B according to the projection of 15 analysts.

Stock to Watch for Earnings: Abbott Laboratories (NYSE:ABT)

Shares of Abbott Laboratories (NYSE:ABT) fell -2.82% to reach at $40.01 during previous trading session. The company has experienced volume of 19.30M shares while on average the company has a capacity of trading 8.03M share.

Abbott Laboratories (NYSE:ABT) on October 19, 2016 announced financial results for the third quarter ended Sept. 30, 2016.

  • Third-quarter worldwide sales of $5.3 billion increased 2.9 percent on a reported basis and 4.0 percent on an operational basis.
  • Reported diluted EPS from continuing operations under GAAP was a $(0.24) loss in the third quarter, primarily due to an adjustment of $(0.66) per share associated with Abbott’s equity investment in Mylan to reflect Mylan’s share price as of Sept. 30, 2016. Excluding specified items, adjusted diluted EPS from continuing operations was $0.59 in the third quarter, at the high end of the previous guidance range.
  • Abbott adjusted its full-year 2016 EPS guidance for continuing operations under GAAP to $0.59 to $0.61, and narrowed and raised at the mid-point its full-year 2016 adjusted EPS for continuing operations to $2.19 to $2.21, exceeding its initial guidance for the year.
  • In the third quarter, Abbott received U.S. FDA approval for its FreeStyle Libre Pro system, a revolutionary continuous glucose monitoring system for healthcare professionals to use with their patients with diabetes; submitted for U.S. regulatory approval a consumer version of FreeStyle Libre, to be used by people with diabetes to self-monitor glucose levels; received U.S. FDA approval for AbsorbTM, the only fully dissolving heart stent; and received U.S. FDA approval for TECNIS Symfony intraocular lenses for the treatment of cataracts, the first and only extended depth of focus lenses for people with cataracts.
  • On Sept. 16, 2016, Abbott announced the sale of Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325 billion. This transaction aligns with Abbott’s shaping of its portfolio, which has recently focused on developing leadership positions in cardiovascular devices and expanding diagnostics. The transaction is expected to close in the first quarter of 2017 and is subject to customary closing conditions, including regulatory approvals.

Abbott Laboratories (NYSE:ABT) holds the market capitalization of $59.65B along with 1.47B outstanding shares. During the last trade, stock’s minimum price has been reached out at $39.94 while the maximum trading price moved at $41.38. Currently the stock price is moving -12.07% off from the highest level of twelve months and +13.22% above from twelve months low. Abbott Laboratories (NYSE:ABT) marked 52-week highest price level of $45.50 on 11/20/15 and 52-week lowest price level of $35.34 on 01/28/16. For the stock, price target value has been calculated at $47.88 based on calls of 13 experts. Stock’s minimum price target estimates has been figured out at $45.00 while the maximum price target forecast is established at $50.00.

As of current trade, Abbott Laboratories (NYSE:ABT) has shown weekly downbeat performance of -2.37%. Its six months performance indicated a bearish movement while its yearly performance reflected a negative trend of -1.73%. Year-to-date (YTD) performance of the stock illustrate downbeat trend of -8.67%. Shares of Abbott Laboratories (NYSE:ABT) currently have an ABR of 1.60, derived from a total of 15 opinions. The company’s price sits -5.44% below from its 50-day moving average of $41.75 and -0.80% below from the stock’s 200-day moving average of $41.36. The company has Relative Strength Index (RSI 14) of 36.34 along with Average True Range (ATR 14) of 0.85. Its weekly and monthly volatility is 2.15%, 1.93% respectively. The company’s beta value is at 1.35.

Abbott Laboratories (NYSE:ABT) currently has a PEG ratio of 3.24 where as its P/E ratio is 30.71. The company’s price to sales ratio for trailing twelve months is 2.87 and price to book ratio for most recent quarter is 2.85, whereas price to cash per share for the most recent quarter is 13.31. Abbott Laboratories (NYSE:ABT)’s price to free cash flow for trailing twelve months is 292.52. Its quick ratio for most recent quarter is 1.20 along with current ratio for most recent quarter of 1.50. Total debt to equity ratio of the company for most recent quarter is 0.41 whereas long term debt to equity ratio for most recent quarter is 0.29. Abbott Laboratories (NYSE:ABT) has a Return on Assets of 5.60%. The company currently has a Return on Equity of 10.90% and Return on Investment of 7.70%.